Open AccessS787 Disparities in Accessibility to Therapy Between California’s Commercial and Governmental Health Care Plans for Patients With Moderate to Severe Ulcerative Colitis
Author(s) -
Kenneth Leung,
Shadi Hamdeh,
Muhammad B. Hammami
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000776680.47395.6f
Subject(s) - formulary , medicine , prior authorization , medicaid , infliximab , golimumab , vedolizumab , tofacitinib , adalimumab , family medicine , ulcerative colitis , pharmacy , health care , pharmacology , disease , rheumatoid arthritis , economics , economic growth